XGN vs MYGN vs NTRA vs CDNA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -1. 6% for Myriad Genetics, Inc. (MYGN). Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -85. 5% for Myriad Genetics, Inc. (MYGN). Over 10 years, the gap is even starker: NTRA returned +1835% versus MYGN's -87. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 17β versus Myriad Genetics, Inc. 's 1. 81β — meaning MYGN is approximately 55% more volatile than NTRA relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 57% for Myriad Genetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -1. 6% for Myriad Genetics, Inc. (MYGN). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 0. 7% year-over-year, compared to -180. 9% for Myriad Genetics, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CareDx, Inc (CDNA) is the more profitable company, earning -5.

6% net margin versus -44. 4% for Myriad Genetics, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -21. 1% for XGN. At the gross margin level — before operating expenses — MYGN leads at 69. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareDx, Inc (CDNA) trades at 23.

3x forward P/E versus 69. 4x for Myriad Genetics, Inc. — 46. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MYGN: 46. 7% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). Myriad Genetics, Inc. (MYGN) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +1835%, MYGN: -87. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XGN is a small-cap high-growth stock; MYGN is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; CDNA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.